Therapy of pulmonary arterial hypertension in systemic sclerosis: An update

被引：6

作者：

Denton C.P. ^{[1
]}

Nihtyanova S.I. ^{[1
]}

机构：

[1] Centre for Rheumatology, Royal Free Hospital, London, NW3 2QG, Pond Street

来源：

Current Rheumatology Reports | 2007年 / 9卷 / 2期

关键词：

Pulmonary Arterial Hypertension; Systemic Sclerosis; Bosentan; Iloprost; Epoprostenol;

D O I：

10.1007/s11926-007-0011-4

中图分类号：

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) affects 10% to 15% of patients with systemic sclerosis and is a major cause for disease-related morbidity and mortality. Over the past decade, significant progress has been made in the understanding of the pathophysiologic mechanisms underlying PAH. This progress led to the development of several new treatment options and, as a result, dramatically improved survival among this severely affected cohort. The outcome in patients with scleroderma-related PAH is much worse than that in patients with idiopathic PAH, and unfortunately only a few studies have assessed treatment and outcome among patients suffering from connective tissue disease-related PAH. In recent years, publications of connective tissue disease subgroup analysis from large trials in PAH have emerged. We review the current treatment options for PAH and the evidence for their use in scleroderma-related PAH. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：158 / 164

页数：6

共 43 条

[1]

Mukerjee D., St George D., Coleiro B., Et al., Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach, Ann Rheum Dis, 62, pp. 1088-1093, (2003)

[2]

Hachulla E., Gressin V., Guillevin L., Et al., Pulmonary arterial hypertension in systemic sclerosis: Definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study), Rev Med Interne, 25, pp. 340-347, (2004)

[3]

Humbert M., Morrell N.W., Archer S.L., Et al., Cellular and molecular pathobiology of pulmonary arterial hypertension [review], J Am Coll Cardiol, 43, 12 SUPPL. S, (2004)

[4]

Barst R.J., Rubin L.J., Long W.A., Et al., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group, N Engl J Med, 334, pp. 296-302, (1996)

[5]

Badesch D.B., Tapson V.F., McGoon M.D., Et al., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial, Ann Intern Med, 132, pp. 425-434, (2000)

[6]

McLaughlin V.V., Shillington A., Rich S., Survival in primary pulmonary hypertension: The impact of epoprostenol therapy, Circulation, 106, pp. 1477-1482, (2002)

[7]

McLaughlin V.V., Gaine S.P., Barst R.J., Et al., Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension, J Cardiovasc Pharmacol, 41, pp. 293-299, (2003)

[8]

Simonneau G., Barst R.J., Galie N., Et al., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med, 165, pp. 800-804, (2002)

[9]

Oudiz R.J., Schilz R.J., Barst R.J., Et al., Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease, Chest, 126, pp. 420-427, (2004)

[10]

Lang I., Gomez-Sanchez M., Kneussl M., Et al., Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension, Chest, 129, pp. 1636-1643, (2006)

← 1 2 3 4 5 →